Weekly administration of paclitaxel in the treatment of metastatic breast cancer: From rational to practice;Le paclitaxel en administration hebdomadaire dans le traitement du cancer du sein métastatique: Du rationnel à la pratique

Bulletin du Cancer

Volumn 89, Issue 3, 2002, Pages 275-282

  Campone, Mario ^a   Fumoleau, Pierre ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Breast cancer; Paclitaxel; Trastuzumab; Weekly administration

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; TRASTUZUMAB;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LEUKOPENIA; METASTASIS; REVIEW; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PACLITAXEL;

EID: 0036219495     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia
2. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer
3. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer
4. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
5. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracydines
6. Single-agent paclitaxel as a first-line treatment of metastatic breast cancer: The British experience
7. 2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC)
8. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for mestastatic breast cancer
9. 3-Hour (hr) high-dose raxol (T) infusion in advanced breast cancer (ABC): A NSABP phase II study
10. Paclitaxel activity in anthracycline refractory breast cancer patients
11. Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy
12. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial
13. Phase II trial of paclitaxel (Taxol®) as first line chemotherapy for metastatic breast cancer (MBC)
14. Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute treatment referral center trial
15. Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independant of prior anthracycline response
16. Phase II trial of paclitaxel 96-hour infusion with G-CSF in anthracycline-resistant metastatic breast cancer
17. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial with 96-hour infusion
18. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
19. A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)
20. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from GALGB 9342
21. Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3- to 24-hr infusion of high-dose Taxol
22. Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (PT) with metastatic breast cancer (MBC)
23. Paclitaxel affects microtubule dynamics and apoptosis
24. Mechanisms of Taxol-induced cell death are concentration dependant
25. The mode of action of Taxol: Apoptosis at low concentration and necrosis at high concentration
26. Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
27. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol
28. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol
29. Taxol resistance: In vitro and in vivo studies in breast cancer and lymphoma
30. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
31. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
32. Tumor size, sensitivity to therapy, and design of treatment schedules
33. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
34. A large phase II trial of paclitaxel administered as a weekly one hour infusion in patients with metastatic breast cancer
35. Phase II study of weekly paclitaxel (P) treatment in recurrent breast cancer after high-dose chemotherapy (HDC)
36. A promising second line treatment with weekly taxol (T) in anthracycline recurrent, advanced breast cancer (ABC) patients (PTS)
37. Long-term weekly paclitaxel over 1 hour infusion with limited premedication: A phase II trial report
38. Phase II study to evaluate the efficacy of weekly paclitaxel (WP) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline (A) ± taxane (T) therapy
39. Weekly moderate-dose paclitaxel (P) in advanced breast cancer (ABC)
40. Activity of weekly paclitaxel in breast cancer recurrences after high dose chemotheray (HDC) with stem cell support
41. Weekly taxanes in treatment of metastatic breast cancer (MBC)
42. Reinduction of response with weekly taxol (T) in advanced breast cancer (ABC)
43. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
44. Comparative evaluation of trastuzumab (Herceptin®) in combination with paclitaxel (Taxol®) or docetaxel (Taxotere®) in Her-2-expressing human breast cancer cell lines
45. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
46. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
47. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
48. Use of chemotherapy plus a monodonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
49. -) metastatic breast cancer (MBC)
50. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analyis of efficacy by HER2 immunophenotype and gene amplification
51. Phase II trial of a weekly Taxol (T), 5-fluorouracil (FU) and leucovorin (LV) regimen in patientes (Pts) with metastatic breast cancer: An update
52. Weekly combination of Taxol, 5-fluorouracil and leucovorin (TFL) in advanced pretreated breast cancer patients
53. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer: A phase II study
54. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: Results of a clinical phase II study
55. Cisplatin-epirubicin-paclitaxel (PET) weekly administration with G-CSF support in advanced breast cancer (ABC): A phase II study